StudyFinder
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
RECRUITING
18 years to 75 years old
Inclusion Criteria:
* Participants are male or female ≥ 18 years up to ≤ 75 years of age.
* Capable of giving signed informed consent and able to comply with the protocol
* Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event
* Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks.
* CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP ≤ 10 mg/L must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation)
* Pericarditis pain score ≥ 4 based on the 11-point NRS.
* Stable doses of NSAIDs, colchicine, and/or oral corticosteroids (if receiving these treatments)
Exclusion Criteria:
* Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases.
* History of clinically significant immunosuppressive disorder, autoimmune/autoinflammatory disorder, or primary or secondary immunodeficiency.
* Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.DRUG: VTX2735, DRUG: VTX2735, DRUG: VTX2735, DRUG: VTX2735, DRUG: VTX2735
Recurrent Pericarditis
Ventyx, Zomagen, Recurrent Pericarditis, VTX2735, NLRP3 Inhibitor, NLRP3, Inflammasome
Ventyx Clinical Trial Contact - ClinicalTrials@ventyxbio.com
NCT06836232